| Erin Holcomb, APRN | |
|
3210 Avenue B, Scottsbluff, NE 69361-4303 | |
| (308) 630-0800 | |
| (308) 630-0842 |
| Full Name | Erin Holcomb |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 12 Years |
| Location | 3210 Avenue B, Scottsbluff, Nebraska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144585225 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 111373 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Regional West Medical Center | Scottsbluff, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regional West Physicians Clinic | 2062301609 | 114 |
News Archive
Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.
Deadly methicillin-resistant Staphylococcus aureus - MRSA - a bacterium that responds poorly to conventional antibiotic treatment, infects 90,000 Americans per year and causes 19,000 deaths, most in hospital settings.
ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.
Inducing cellular immunity as a means to protect against influenza virus is the focus of several laboratories at the Trudeau Institute. Researchers here have recently identified two important signaling components required by the immune system that might allow us to pre-position our own virus-fighting T cells to the lungs, the site of initial infection.
Researchers have demonstrated the feasibility of delivering an RNA that encodes for the protein alpha-1-antitrypsin (AAT)-which is missing or nonfunctional in the genetic disorder AAT deficiency-into cells in the laboratory, enabling the cells to produce highly functional AAT.
› Verified 5 days ago
| Entity Name | Regional West Physicians Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306910534 PECOS PAC ID: 2062301609 Enrollment ID: O20040315001274 |
News Archive
Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.
Deadly methicillin-resistant Staphylococcus aureus - MRSA - a bacterium that responds poorly to conventional antibiotic treatment, infects 90,000 Americans per year and causes 19,000 deaths, most in hospital settings.
ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.
Inducing cellular immunity as a means to protect against influenza virus is the focus of several laboratories at the Trudeau Institute. Researchers here have recently identified two important signaling components required by the immune system that might allow us to pre-position our own virus-fighting T cells to the lungs, the site of initial infection.
Researchers have demonstrated the feasibility of delivering an RNA that encodes for the protein alpha-1-antitrypsin (AAT)-which is missing or nonfunctional in the genetic disorder AAT deficiency-into cells in the laboratory, enabling the cells to produce highly functional AAT.
› Verified 5 days ago
| Entity Name | Quick Care Medical Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477570281 PECOS PAC ID: 8729058680 Enrollment ID: O20040728000702 |
News Archive
Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.
Deadly methicillin-resistant Staphylococcus aureus - MRSA - a bacterium that responds poorly to conventional antibiotic treatment, infects 90,000 Americans per year and causes 19,000 deaths, most in hospital settings.
ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.
Inducing cellular immunity as a means to protect against influenza virus is the focus of several laboratories at the Trudeau Institute. Researchers here have recently identified two important signaling components required by the immune system that might allow us to pre-position our own virus-fighting T cells to the lungs, the site of initial infection.
Researchers have demonstrated the feasibility of delivering an RNA that encodes for the protein alpha-1-antitrypsin (AAT)-which is missing or nonfunctional in the genetic disorder AAT deficiency-into cells in the laboratory, enabling the cells to produce highly functional AAT.
› Verified 5 days ago
| Entity Name | Kimball County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326027160 PECOS PAC ID: 5799751004 Enrollment ID: O20040908000971 |
News Archive
Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.
Deadly methicillin-resistant Staphylococcus aureus - MRSA - a bacterium that responds poorly to conventional antibiotic treatment, infects 90,000 Americans per year and causes 19,000 deaths, most in hospital settings.
ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.
Inducing cellular immunity as a means to protect against influenza virus is the focus of several laboratories at the Trudeau Institute. Researchers here have recently identified two important signaling components required by the immune system that might allow us to pre-position our own virus-fighting T cells to the lungs, the site of initial infection.
Researchers have demonstrated the feasibility of delivering an RNA that encodes for the protein alpha-1-antitrypsin (AAT)-which is missing or nonfunctional in the genetic disorder AAT deficiency-into cells in the laboratory, enabling the cells to produce highly functional AAT.
› Verified 5 days ago
| Entity Name | Cheyenne County Hospital Association Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487736963 PECOS PAC ID: 1658345657 Enrollment ID: O20050301000906 |
News Archive
Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.
Deadly methicillin-resistant Staphylococcus aureus - MRSA - a bacterium that responds poorly to conventional antibiotic treatment, infects 90,000 Americans per year and causes 19,000 deaths, most in hospital settings.
ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.
Inducing cellular immunity as a means to protect against influenza virus is the focus of several laboratories at the Trudeau Institute. Researchers here have recently identified two important signaling components required by the immune system that might allow us to pre-position our own virus-fighting T cells to the lungs, the site of initial infection.
Researchers have demonstrated the feasibility of delivering an RNA that encodes for the protein alpha-1-antitrypsin (AAT)-which is missing or nonfunctional in the genetic disorder AAT deficiency-into cells in the laboratory, enabling the cells to produce highly functional AAT.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erin Holcomb, APRN 3210 Avenue B, Scottsbluff, NE 69361-4303 Ph: (308) 630-0800 | Erin Holcomb, APRN 3210 Avenue B, Scottsbluff, NE 69361-4303 Ph: (308) 630-0800 |
News Archive
Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.
Deadly methicillin-resistant Staphylococcus aureus - MRSA - a bacterium that responds poorly to conventional antibiotic treatment, infects 90,000 Americans per year and causes 19,000 deaths, most in hospital settings.
ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.
Inducing cellular immunity as a means to protect against influenza virus is the focus of several laboratories at the Trudeau Institute. Researchers here have recently identified two important signaling components required by the immune system that might allow us to pre-position our own virus-fighting T cells to the lungs, the site of initial infection.
Researchers have demonstrated the feasibility of delivering an RNA that encodes for the protein alpha-1-antitrypsin (AAT)-which is missing or nonfunctional in the genetic disorder AAT deficiency-into cells in the laboratory, enabling the cells to produce highly functional AAT.
› Verified 5 days ago
Penny Marie Sanderson, APRN, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1517 Broadway, Suite 124, Scottsbluff, NE 69361 Phone: 308-635-2800 Fax: 308-635-2801 | |
Mr. Stephen E Schlickbernd, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3210 Avenue B, Scottsbluff, NE 69361 Phone: 308-630-0800 Fax: 308-630-0842 | |
Alice Fillingham, APRN-NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4021 Avenue B, Scottsbluff, NE 69361 Phone: 308-630-2689 | |
Jennifer Griebel, APRN FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3911 Avenue B Ste 1110, Scottsbluff, NE 69361 Phone: 308-630-2100 Fax: 308-630-2139 | |
Brittany Christine Mcdonald, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3210 Avenue B, Scottsbluff, NE 69361 Phone: 308-630-0800 | |
Rhonda Smith, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2 W 42nd St # 3100, Scottsbluff, NE 69361 Phone: 308-632-2872 |